Apoptosis in Neurodegeneration

Introduction

Apoptosis In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Apoptosis is a highly regulated form of programmed cell death characterized by cell shrinkage, chromatin condensation, membrane blebbing, and the formation of apoptotic bodies ^{1Exploring apoptotic pathways: implications for neurodegeneration2025 · Front Cell Dev Biol · PMID 40190072Open reference} that are phagocytosed without triggering inflammation. During neural development, apoptosis is essential for eliminating excess neurons and sculpting ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference} functional circuits — approximately 50% of all neurons generated during embryogenesis are removed by developmental apoptosis. However, aberrant activation of apoptotic pathways ^{3Molecular cell biology of anastasis: recovery from the brink of apoptotic cell death2017 · Mol Cell · PMID 28855258Open reference} contributes to neuronal loss in Alzheimer’s disease, Parkinson’s disease, ALS, Huntington’s disease, and other neurodegenerative ^{4The pathophysiology of mitochondrial cell death2004 · Science · PMID 15286356Open reference} conditions^{5Apoptosis in the nervous system2000 · Nature · PMID 11027887Open reference 1Exploring apoptotic pathways: implications for neurodegeneration2025 · Front Cell Dev Biol · PMID 40190072Open reference}. Apoptosis is now understood as one component of a broader network of regulated cell ^{6miR-277 targets the proapoptotic gene Hid to ameliorate Aβ42-mediated neurodegeneration2023 · Cell Death Dis · PMID 38098170Open reference} death mechanisms — ^{7Tau cleavage by caspase-3 generates aggregation-prone fragments2003 · Cell · PMID 12574404Open reference} including necroptosis, ^{8Fas-mediated motor neuron apoptosis via Daxx-ASK1 pathway2004 · Nat Cell Biol · PMID 15077149Open reference} ferroptosis, pyroptosis, and parthanatos — that collectively drive neurodegeneration^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}. ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}0

A critical emerging concept is that the boundary between cell survival and death is not absolute: neurons can halt and recover from ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}1 late-stage apoptosis through a process termed anastasis (“rising to life”), challenging the long-held view that apoptotic commitment is ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}2 irreversible^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}3. ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}4

Molecular Pathways

flowchart TD
    subgraph Triggers["Pathological Triggers"]
        A["Amyloid-Beta"] --> AB
        B["Tau Pathology"] --> AB
        C["Oxidative Stress"] --> AB
        D["DNA Damage"] --> AB
        E["ER Stress"] --> AB
        F["Protein Aggregation"] --> AB
        G["Growth Factor Withdrawal"] --> AB
        H["Mitochondrial Dysfunction"] --> AB
        I["Neuroinflammation"] --> AB
        J["Excitotoxicity"] --> AB
    end

    subgraph Intrinsic["Intrinsic Pathway"]
        AB["Stress Signals"] --> BH3["BH3-Only Proteins<br/>Bim, Bad, Puma, Noxa"]
        BH3 --> BCL["BCL-2 Family Balance"]
        BCL --> Anti["Anti-Apoptotic<br/>BCL-2, Bcl-xL, Mcl-1"]
        BCL --> Pro["Pro-Apoptotic<br/>Bax, Bak"]
        Pro --> MOMP["MOMP<br/>Cytochrome c Release"]
        MOMP --> Apop["Apoptosome Formation<br/>Apaf-1 + Caspase-9"]
        Apop --> Casp["Caspase Cascade<br/>Caspase-3, 6, 7"]
        Casp --> Death["Cell Death<br/>Neuronal Loss"]
    end

    subgraph Extrinsic["Extrinsic Pathway"]
        TNF["TNF-alpha"] --> TNFR1["TNFR1"]
        FASL["FasL"] --> FAS["Fas/CD95"]
        TRAIL["TRAIL"] --> DR5["DR4/DR5"]
        TNFR1 --> DISC["DISC Formation"]
        FAS --> DISC
        DR5 --> DISC
        DISC --> Casp8["Caspase-8/10"]
        Casp8 --> Bid["Cleaved Bid -> tBid"]
        Bid --> MOMP2["MOMP Amplification"]
        MOMP2 --> Casp
    end

    subgraph p53["p53 Pathway"]
        DNA_DMG["DNA Damage"] --> P53["p53 Activation"]
        OX_ST["Oxidative Stress"] --> P53
        P53 --> TX["TX: Bax, Puma, Noxa"]
        P53 --> CYTO["p53 Cytochrome c<br/>Direct Bax Activation"]
        TX --> MOMP3["MOMP"]
        CYTO --> MOMP3
    end

    subgraph Disease["Disease Outcomes"]
        Casp --> AD["Alzheimer's Disease"]
        Casp --> PD["Parkinson's Disease"]
        Casp --> ALS["ALS"]
        Casp --> HD["Huntington's Disease"]
        Death --> ATROPHY["Brain Atrophy"]
    end

    Anti -.->|"Inhibit"| Pro
    style Triggers fill:#0a1929,stroke:#333
    style Intrinsic fill:#3e2200,stroke:#333
    style Extrinsic fill:#0a1929,stroke:#333
    style p53 fill:#3e2200,stroke:#333
    style Disease fill:#3a3000,stroke:#333

Intrinsic (Mitochondrial) Pathway

The intrinsic pathway is the dominant apoptotic mechanism in neurodegeneration, triggered by intracellular stress signals including oxidative stress, DNA damage, ER stress, growth factor withdrawal, and protein aggregation.

1. Stress sensing: BH3-only proteins (Bad, Bid, Bim, Puma, Noxa) are activated by specific stress signals. Bim is particularly important in neurons — it is induced by growth factor deprivation and transcriptionally upregulated by FoxO transcription factors

2. Bcl-2 family regulation:

• Pro-apoptotic effectors: Bax and Bak oligomerize in the mitochondria outer membrane to form proteolipid pores

• Anti-apoptotic guardians: Bcl-2, Bcl-xL, and Mcl-1 sequester BH3-only proteins and prevent Bax/Bak activation

• The balance between pro- and anti-apoptotic Bcl-2 family members determines cell fate — this “apoptotic rheostat” is shifted toward death in aging and neurodegeneration

3. Mitochondrial outer membrane permeabilization (MOMP): Bax/Bak pores release cytochrome c, Smac/DIABLO, Omi/HtrA2, AIF, and endonuclease G from the intermembrane space^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}5 ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}6

4. Apoptosome formation: Cytochrome c binds Apaf-1, which recruits pro-caspase-9](/proteins/caspase)-9) via CARD domain interactions, forming the heptameric apoptosome (~700 kDa complex)

5. Caspase cascade: Caspase-9 activates executioner caspases (caspase-3](/proteins/caspase)-3), -6, -7), which cleave >1,000 cellular substrates to dismantle the cell in an orderly fashion

Extrinsic (Death Receptor) Pathway

Triggered by extracellular ligands binding death receptors of the TNF receptor superfamily: ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}7

| Receptor | Ligand | Adaptor | Key Role in Neurodegeneration | ^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}8 |----------|--------|---------|-------------------------------| | Fas (CD95) | FasL | FADD | ALS motor neuron death | | TNFR1 | TNF-alpha | TRADD/FADD | neuroinflammation-mediated death | | DR4/DR5 | TRAIL | FADD | Ischemic neuronal death | | p75NTR | ProNGF | NRAGE/NADE | Basal forebrain cholinergic neuron death in AD |

Ligand binding triggers DISC (death-inducing signaling complex) formation, activating initiator caspase-8 and -10. In type II cells (including most neurons), caspase-8 cleaves Bid to tBid, which activates the intrinsic pathway, amplifying the death signal. This convergence means that extrinsic pathway activation in neurons ultimately depends on mitochondria amplification.

p53-Mediated Apoptosis

The tumor suppressor p53 plays an increasingly recognized role in neuronal apoptosis:

• Transcriptional activation: p53 induces expression of pro-apoptotic genes (Bax, Puma, Noxa, APAF1, Fas) in response to DNA damage and oxidative stress

• Transcription-independent functions: Cytoplasmic p53 directly activates Bax at the mitochondria membrane, bypassing the need for gene transcription

• Elevated in neurodegeneration: p53 levels are increased in AD hippocampus, PD substantia nigra, and ALS motor neurons

• Conformational mutant p53: “Unfolded” p53 conformers accumulate in AD brain, potentially acting as seeds for prion-like spreading of p53 dysfunction^{2Editorial: Cell death mechanisms in neurodegenerative disorders2024 · Front Cell Dev Biol · PMID 38913310Open reference}9.

Morphological and Biochemical Features

Distinguishing Apoptosis from Other Cell Death Forms

Detection Methods

• TUNEL assay: Detects DNA fragmentation (3’-OH labeling); widely used but not specific to apoptosis

• Annexin V binding: Detects phosphatidylserine externalization on outer membrane leaflet

• Caspase activity assays: Fluorometric substrates (DEVD-AFC for caspase-3](/proteins/caspase)-3), LEHD-AFC for caspase-9](/proteins/caspase)-9))

• Cytochrome c release: Immunofluorescence or subcellular fractionation detecting mitochondria release

• PARP cleavage: Western blot for 89 kDa fragment (from 116 kDa full-length)

• Live imaging: CaspGlow probes and IncuCyte real-time analysis enable longitudinal tracking of apoptosis in neuronal cultures

Apoptosis in Specific Neurodegenerative Diseases

Alzheimer’s Disease

Multiple pathogenic processes converge on apoptotic pathways in AD:

• amyloid-beta toxicity: Oligomeric Aβ activates both intrinsic and extrinsic pathways; triggers mitochondria dysfunction], calcium dysregulation, and oxidative stress. Aβ oligomers also activate caspase-2 through a PIDD-RAIDD complex

• Tau pathology: Hyperphosphorylated tau impairs axonal transport, leading to energy failure and mitochondria stress; caspase-3](/proteins/caspase)-3) cleaves tau at Asp421, generating toxic fragments that propagate further tau pathology]

• neuroinflammation: Microglial TNF-alpha and FasL activate the extrinsic pathway; NLRP3 inflammasome] activation promotes caspase-1](/proteins/caspase)-1)-dependent neuronal injury

• Neurotrophic factor withdrawal: Loss of NGF signaling through p75NTR triggers basal forebrain cholinergic neuron apoptosis, contributing to early acetylcholine deficits

• ER stress: Chronic UPR activation by Aβ and tau induces CHOP-mediated apoptosis

• miRNA dysregulation: miR-277 and other microRNAs modulate pro-apoptotic gene expression; therapeutic targeting of specific miRNAs can ameliorate Aβ-mediated neurodegeneration^{3Molecular cell biology of anastasis: recovery from the brink of apoptotic cell death2017 · Mol Cell · PMID 28855258Open reference}0

• Excitotoxicity: Striatal neurons are hypersensitive to NMDA receptor-mediated excitotoxicity, which activates calpains and caspases synergistically

• Energy deficits: Impaired mitochondria energy production lowers the threshold for apoptotic activation

Anastasis: Recovery from the Brink of Apoptosis

One of the most surprising discoveries in cell death biology is anastasis — the ability of cells to halt and reverse the apoptotic program even after cytochrome c release, caspase activation, DNA fragmentation, and membrane blebbing^{3Molecular cell biology of anastasis: recovery from the brink of apoptotic cell death2017 · Mol Cell · PMID 28855258Open reference}1.

Mechanisms of Anastasis

Cells recovering from apoptosis activate a coordinated survival program:

• XIAP upregulation: Inhibits caspase-3](/proteins/caspase)-3), -7, and -9, arresting the caspase-mediated destruction cascade

• Pro-survival Bcl-2 family: AKT1 activation and upregulation of Bcl-2 family members suppress further MOMP

• MDM2 induction: Suppresses p53-mediated death signaling, allowing cell cycle re-entry

• DNA repair: PARP-1 and GADD45G coordinate repair of apoptosis-induced DNA damage; DFF45/ICAD re-inhibits the CAD nuclease

• autophagy activation: ATG12 and SQSTM1/p62-mediated selective autophagy removes damaged mitochondria and other organelles

• Antioxidant response: HO-1 neutralizes free radicals generated during apoptosis

Neuronal Anastasis

neurons appear capable of anastasis, with important implications for neurodegeneration:

• Stressed neurons can recover from membrane blebbing, nuclear condensation, and mitochondria fragmentation — but not from cytochrome c release beyond a critical threshold^{3Molecular cell biology of anastasis: recovery from the brink of apoptotic cell death2017 · Mol Cell · PMID 28855258Open reference}2

• Photoreceptor cells recover from caspase-3](/proteins/caspase)-3) activation and PARP cleavage through mitophagy-dependent restoration of ATP levels and reduction of mitochondria ROS^{3Molecular cell biology of anastasis: recovery from the brink of apoptotic cell death2017 · Mol Cell · PMID 28855258Open reference}3

• Anastasis may explain the prolonged time course of neuronal loss in chronic neurodegenerative diseases — neurons may cycle through sub-lethal apoptotic episodes over years before final commitment

• Enhancing anastasis could represent a novel therapeutic strategy complementary to direct caspase inhibition

Neuronal Resistance to Apoptosis

Mature neurons possess unique mechanisms to resist apoptosis:

• High Bcl-2 and Bcl-xL expression: Provides a substantial buffer against MOMP; expression declines with aging

• X-linked inhibitor of apoptosis protein (XIAP): Directly inhibits caspases-3, -7, and -9 through BIR domain interactions

• Neuronal IAPs: cIAP1 and cIAP2 ubiquitinate RIPK1, preventing it from triggering cell death

• Survival signaling: Active PI3K/Akt/mTOR pathway phosphorylates and inactivates Bad, caspase-9](/proteins/caspase)-9), and FoxO transcription factors

• CREB-dependent transcription: Neuronal activity-dependent CREB activation maintains expression of Bcl-2 and BDNF

• High apoptotic threshold: neurons maintain higher levels of anti-apoptotic proteins relative to other cell types, requiring stronger pro-apoptotic signals for commitment

These resistance mechanisms decline with aging — reduced Bcl-2 expression, impaired Akt signaling, and accumulated oxidative damage lower the apoptotic threshold in aged neurons, potentially explaining the age-dependence of neurodegenerative diseases.

Caspase-Independent Apoptosis-Like Death

Some forms of neuronal death share features with apoptosis but do not require caspases:

• AIF (apoptosis-inducing factor): Released from mitochondria during MOMP; translocates to the nucleus and induces large-scale DNA fragmentation (~50 kb) and chromatin condensation independently of caspases

• Endonuclease G: Nuclear translocation after MOMP; cleaves DNA at nucleosomal sites

• Omi/HtrA2: Serine protease released from mitochondria; degrades IAPs (removing caspase inhibition) and directly cleaves cytoskeletal proteins

• Parthanatos: PARP-1 hyperactivation triggers AIF release from mitochondria; important in ischemic brain injury and may contribute to PD

These pathways explain why caspase inhibitors alone often fail to fully prevent neuronal death in disease models.

Therapeutic Strategies

Anti-Apoptotic Approaches

Combination Approaches

Given that multiple cell death pathways operate simultaneously in neurodegeneration, combination strategies targeting apoptosis alongside other death mechanisms are increasingly explored:

• Caspase inhibitor + necrostatin-1: Blocks both apoptosis and necroptosis

• Caspase inhibitor + ferrostatin-1: Blocks both apoptosis and ferroptosis

• Anti-apoptotic + anti-inflammatory: Minocycline + NSAID combinations in preclinical models

• Neurotrophic factor + autophagy enhancer: Supporting survival while clearing toxic aggregates

Key Challenges

• blood-brain barrier: Delivery of large molecules (neurotrophic factors, antibodies) remains difficult; focused ultrasound and bispecific antibody shuttles are being developed

• Timing: Intervention must occur before irreversible commitment; by the time of clinical diagnosis, substantial neuronal loss has already occurred

• Selectivity: Systemic caspase inhibition may promote tumorigenesis; CNS-restricted approaches are needed

• Multiple death pathways: Blocking apoptosis alone shifts neurons to alternative death mechanisms (necroptosis, ferroptosis), requiring multi-pathway targeting^{3Molecular cell biology of anastasis: recovery from the brink of apoptotic cell death2017 · Mol Cell · PMID 28855258Open reference}5

• Sublethal caspase activity: Low-level caspase activation serves physiological roles in synaptic pruning and plasticity; complete blockade may impair normal neural function

Microglial Apoptosis and Self-Regulation

An emerging area of research is the role of apoptosis in microglial self-regulation:

• Activated microglia undergo apoptosis to limit inflammatory responses

• CSF1R inhibitors (PLX3397/pexidartinib) deplete microglia — Key neuronal survival factor

• Neuroinflammation — Inflammatory responses in the CNS

• Reactive oxygen species — Free radical biology

External Links

• KEGG: Apoptosis Pathway

• Reactome: Apoptosis

• UniProt: Caspase-3 (CASP3)

Background

The study of Apoptosis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: Apoptosis in Neurodegeneration expression search

• Allen Mouse Brain Atlas: Apoptosis in Neurodegeneration search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Apoptosis in Neurodegeneration developmental expression

See Also

• Diseases Index

Conclusion

Apoptosis is a fundamental cellular process that plays a critical role in neurodegenerative diseases. While programmed cell death is essential for normal brain development and homeostasis, dysregulation of apoptotic pathways contributes to the progressive loss of neurons in conditions such as Alzheimer’s disease, Parkinson’s disease, ALS, and Huntington’s disease. Understanding the molecular mechanisms that govern neuronal apoptosis—including caspase activation, mitochondria dysfunction, and the interplay with neuroinflammation—offers promising avenues for therapeutic intervention. Targeting anti-apoptotic pathways, enhancing neurotrophic support, and modulating inflammatory responses represent key strategies for developing disease-modifying treatments for neurodegenerative disorders. Continued research into the cell-type specificity of apoptotic vulnerability and the development of biomarkers for early detection will be essential for translating these insights into clinical benefits for patients.

Clinical Translation and Therapeutic Implications

Current Therapeutic Approaches

Given the central role of apoptosis in neurodegeneration, multiple therapeutic strategies targeting apoptotic pathways are under development:

Caspase Inhibitors

• Broad-spectrum caspase inhibitors (z-VAD-fmk): Have shown neuroprotective effects in preclinical models but limited clinical translation due to poor brain penetration and systemic toxicity

• VX-765 (linvenilast): A selective caspase-1 inhibitor that completed Phase II trials for epilepsy; being explored for neurodegenerative applications ClinicalTrials.gov

• Emricasan: A pan-caspase inhibitor that reached Phase II for liver disease; preclinical studies in neurodegeneration showed reduced neuronal loss doi:10.1016/j.neurobiolaging.2024.01.015

Bcl-2 Family Modulators

• Bcl-2 inhibitors (venetoclax): Originally developed for hematological malignancies; being re-purposed for neurodegeneration based on anti-apoptotic Bcl-2 elevation in AD brains doi:10.1186/s13195-023-01289-4

• Bax inhibitors: Peptide-based Bax inhibiting peptides (BIP) have shown promise in preclinical PD models doi:10.1038/s41583-023-00756-x

• BH4 domain mimetics: Designed to mimic the anti-apoptotic function of Bcl-xL; early-stage development

Neurotrophic Factors

• BDNF delivery: Gene therapy approaches (AAV-BDNF) have reached early-phase trials for AD; challenges include BBB penetration and expression control

• GDNF: Phase I/II trials for PD showed mixed results; continuous infusion required for efficacy doi:10.1002/mds.28570

• NGF: AAV-NGF (CERE-110) reached Phase II for AD; showed some benefit in cholinergic neuron preservation

Repurposed Drugs with Anti-Apoptotic Activity

• Minocycline: Inhibits cytochrome c release and has anti-inflammatory properties; Phase III trial in ALS was negative; modest effects in PD/HD trials doi:10.1016/j.pharmthera.2024.108456

• Lithium: Inhibits GSK3β and promotes Bcl-2 expression; mixed results in AD/HD trials

• Rapamycin/mTOR inhibitors: Activate autophagy while inhibiting apoptosis; mTOR inhibitors in AD trials

Novel Approaches

• Anastasis enhancers: Compounds promoting recovery from sub-lethal apoptotic activation; early research phase

• p53 modulators: Pifithrin-alpha and derivatives block p53-mediated apoptosis; cancer risk limits clinical use

• ASO/siRNA therapy: Targeting specific pro-apoptotic genes (Bim, CHOP); delivery remains challenging

Biomarker Development

Clinical Trials Overview

Several clinical trials target apoptotic pathways in neurodegeneration:

Patient Impact

Alzheimer’s Disease

• Apoptosis contributes to progressive hippocampal neuron loss, driving cognitive decline

• Early intervention may preserve synaptic function before irreversible damage

• Cholinergic neurons in basal forebrain show particular vulnerability via p75NTR-mediated apoptosis

Parkinson’s Disease

• Dopaminergic neurons in substantia nigra undergo apoptosis in response to α-synuclein aggregation, mitochondrial dysfunction, and oxidative stress

• Anti-apoptotic strategies could slow disease progression if applied early

Amyotrophic Lateral Sclerosis

• Motor neuron apoptosis driven by excitotoxicity, mitochondrial dysfunction, and TDP-43 pathology

• Modulating apoptosis may preserve respiratory function longer

Huntington’s Disease

• Striatal neuron apoptosis mediated by mutant huntingtin, energy deficits, and excitotoxicity

• Early anti-apoptotic intervention could preserve function before symptom onset

Challenges and Future Directions

Key Challenges:

1. BBB penetration: Most anti-apoptotic compounds are large molecules or have poor brain penetration

2. Timing: By clinical diagnosis, significant apoptosis has already occurred; need biomarkers for earlier detection

3. Selectivity: Systemic caspase inhibition risks tumorigenesis and impairs physiological functions (synaptic pruning)

4. Pathway redundancy: Blocking apoptosis shifts neurons to alternative death mechanisms (necroptosis, ferroptosis)

5. Sublethal caspase activity: Low-level caspase activation serves physiological roles in plasticity; complete blockade may be detrimental

Future Directions:

• Combination therapy: Targeting multiple cell death pathways simultaneously (apoptosis + necroptosis + ferroptosis)

• Biomarker-driven trials: Using caspase cleavage products to select patients and monitor response

• Anastasis-based approaches: Promoting neuronal recovery from sub-lethal apoptotic activation

• Cell-type specific delivery: Targeted delivery to specific neuronal populations using AAV serotypes or antibody shuttles

• Precision medicine: Genetic profiling to identify patients with specific apoptotic pathway vulnerabilities

References

1. Bhatt P et al., Exploring apoptotic pathways: implications for neurodegeneration (2025)

2. Yuan J et al., Apoptosis in the nervous system (2000)

3. Green DR et al., The pathophysiology of mitochondrial cell death (2004)

4. Sun G et al., Molecular cell biology of anastasis (2017)

5. Graham RK et al., Cleavage at the caspase-6 site is required for neuronal dysfunction (2006)

6. Minocycline in ALS: Clinical trials and outcomes

7. Venetoclax in neurodegeneration: Preclinical findings

8. GDNF trials in Parkinson’s disease

Pathway Diagram

The following diagram shows the key molecular relationships involving Apoptosis in Neurodegeneration discovered through SciDEX knowledge graph analysis:

graph TD
    entities_ferroptosis["entities-ferroptosis"] -->|"involved in"| apoptosis["apoptosis"]
    P53["P53"] -->|"activates"| apoptosis["apoptosis"]
    caspase_family["caspase family"] -->|"activates"| apoptosis["apoptosis"]
    BAX["BAX"] -->|"promotes"| apoptosis["apoptosis"]
    BCL_2["BCL-2"] -->|"regulates"| apoptosis["apoptosis"]
    hepatocytes["hepatocytes"] -->|"involved in"| apoptosis["apoptosis"]
    BCL2_inhibitors["BCL2 inhibitors"] -->|"promotes"| apoptosis["apoptosis"]
    FBL["FBL"] -->|"mediates"| apoptosis["apoptosis"]
    BCL_2_inhibitors["BCL-2 inhibitors"] -->|"promotes"| apoptosis["apoptosis"]
    ASPP1["ASPP1"] -->|"promotes"| apoptosis["apoptosis"]
    P53["P53"] -->|"regulates"| apoptosis["apoptosis"]
    PI3K_AKT_GSK3_["PI3K/AKT/GSK3β"] -.->|"inhibits"| apoptosis["apoptosis"]
    BCL2["BCL2"] -.->|"inhibits"| apoptosis["apoptosis"]
    BAX["BAX"] -->|"activates"| apoptosis["apoptosis"]
    BCL2_family["BCL2 family"] -->|"regulates"| apoptosis["apoptosis"]
    style entities_ferroptosis fill:#4fc3f7,stroke:#333,color:#000
    style apoptosis fill:#4fc3f7,stroke:#333,color:#000
    style P53 fill:#4fc3f7,stroke:#333,color:#000
    style caspase_family fill:#4fc3f7,stroke:#333,color:#000
    style BAX fill:#ce93d8,stroke:#333,color:#000
    style BCL_2 fill:#4fc3f7,stroke:#333,color:#000
    style hepatocytes fill:#80deea,stroke:#333,color:#000
    style BCL2_inhibitors fill:#ff8a65,stroke:#333,color:#000
    style FBL fill:#4fc3f7,stroke:#333,color:#000
    style BCL_2_inhibitors fill:#ff8a65,stroke:#333,color:#000
    style ASPP1 fill:#4fc3f7,stroke:#333,color:#000
    style PI3K_AKT_GSK3_ fill:#81c784,stroke:#333,color:#000
    style BCL2 fill:#ce93d8,stroke:#333,color:#000
    style BCL2_family fill:#ce93d8,stroke:#333,color:#000